Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Access the on-demand webcast here HOUSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a
Annamycin delivering better performance 7 th line than would be expected even in 2 nd line for monotherapy
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
12:20pm, Wednesday, 14'th May 2025
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Walter Klemp - Founder, President, CEO and Chairm
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update
07:30am, Wednesday, 14'th May 2025
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
08:40am, Monday, 12'th May 2025
Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast
09:00am, Wednesday, 07'th May 2025
HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin
09:00am, Tuesday, 06'th May 2025
Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers Ongoing pivotal, adaptive Phase 3 clinical trial (the “MIRAC
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents
08:45am, Monday, 05'th May 2025
Company continues to expand global IP coverage and claims to major markets, now extending to June 2040 HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistica
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
08:30am, Thursday, 17'th Apr 2025
HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidate
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
11:01am, Tuesday, 01'st Apr 2025
Moleculin Biotech (MBRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
08:30am, Tuesday, 01'st Apr 2025
– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharm
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
01:00pm, Wednesday, 26'th Mar 2025
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript
10:50am, Monday, 24'th Mar 2025
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Walter Klemp - Chairman and CEO John Paul Waymack - Senior CMO Jonathan Foster -
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
07:05am, Monday, 24'th Mar 2025
– Continued progress in pivotal, adaptive Phase 3 clinical trial (the “MIRACLE” trial) toward first subject treated, on track to take place in the first quarter of 2025
